The purpose of the study is to determine if this new shorter treatment works as well as the conventional longer treatments that have been used in France between 2006 and 2022. The medications will be taken by mouth daily for up to 24 weeks. The treatment success will be evaluated 18 months after starting the medication.

During the study, participants will receive the combination of these five medications in the form of tablets or capsules. The medications will be given in specific daily doses: bedaquiline 400 mg, pretomanid 200 mg, linezolid 600 mg, moxifloxacin 400 mg, and clofazimine 200 mg. This new treatment approach aims to provide a shorter and potentially more effective option for people with MDR-TB.

Participants diagnosed with tuberculosis will receive standard treatment consisting of two medication combinations. The first combination includes isoniazid, pyrazinamide, rifampicin, and ethambutol hydrochloride taken as tablets for two months. This is followed by a second combination of isoniazid and rifampicin tablets for four months. Throughout the treatment period, researchers will collect blood samples to measure various indicators of disease activity.

The study will also use advanced imaging techniques including PET/MRI scans to monitor how the disease responds to treatment. These scans create detailed pictures of the lungs and can show how the infection changes over time. Blood and sputum (mucus coughed up from the lungs) samples will be collected to measure various substances that might indicate how well the treatment is working.

The purpose of the study is to explore the safety and initial effectiveness of these two treatments in helping patients recover lung function and clear the infection. Participants will be randomly assigned to receive either the new treatments or a placebo, in addition to their regular tuberculosis medication. The study will last for up to 24 months, with regular check-ups to monitor health and progress.

Throughout the study, doctors will assess how well the treatments work by looking at lung function and the ability to clear the tuberculosis infection. The goal is to find out if these additional treatments can help improve outcomes for patients with this challenging form of tuberculosis. The study will compare the results of those taking CC-11050 and Metformin to those who do not receive these additional treatments.

Participants in the study will receive either Gremubamab or a placebo, which is a substance with no active medication, through an intravenous infusion, meaning it is administered directly into the vein. The study will last for a total of 12 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see if Gremubamab can help reduce the bacterial burden in the lungs, potentially leading to fewer infections and improved lung function.

The trial is designed to gather important information about the potential benefits of Gremubamab for people with bronchiectasis and chronic Pseudomonas aeruginosa infection. By participating in this study, researchers hope to find a new way to manage this challenging condition and improve the quality of life for those affected. The study will follow a structured schedule, with assessments at various points to track progress and gather data on the treatment’s effectiveness.

Participants in the study will receive either the new combination of drugs or the standard treatment. The study will last for a period of eight weeks, during which the health and progress of the participants will be closely monitored. The goal is to determine if the new treatment can more effectively clear the infection from the lungs and improve patient outcomes compared to the standard treatment. The study will also assess the safety of the new treatment by monitoring any side effects that participants may experience.

Throughout the trial, researchers will collect data on how well the treatment works in reducing the presence of bacteria in the lungs and how well participants tolerate the medications. This information will help in understanding the potential benefits and risks of using high-dose rifampicin, moxifloxacin, and linezolid for treating pulmonary tuberculosis. The findings from this study could lead to improved treatment options for patients suffering from this serious lung infection.

The purpose of this research is to determine if adding cysteamine to regular tuberculosis treatment is safe and well-tolerated by patients. The study involves taking cysteamine capsules by mouth along with standard tuberculosis medications. Participants will need to stay in the hospital for 4 weeks during the treatment period.

During the study, doctors will monitor how well patients tolerate the combined treatment and collect blood and other samples to understand how the medications work together. They will also track any side effects that may occur and measure how effectively the treatment fights the tuberculosis infection. The total duration of the study treatment and follow-up is 6 months.